Literature DB >> 34657442

Screening Rates for Primary Aldosteronism Among Individuals With Hypertension Plus Hypokalemia: A Population-Based Retrospective Cohort Study.

Gregory L Hundemer1, Haris Imsirovic2, Anand Vaidya3, Nicholas Yozamp3, Rémi Goupil4, François Madore4, Mohsen Agharazii5, Greg Knoll1, Manish M Sood1,2.   

Abstract

Primary aldosteronism is a common, yet highly underdiagnosed, cause of hypertension that leads to disproportionately high rates of cardiovascular disease. Hypertension plus hypokalemia is a guideline-recommended indication to screen for primary aldosteronism, yet the uptake of this recommendation at the population level remains unknown. We performed a population-based retrospective cohort study of adults ≥18 years old in Ontario, Canada, with hypertension plus hypokalemia (potassium <3.5 mEq/L) from 2009 to 2015 with follow-up through 2017. We measured the proportion of individuals who underwent primary aldosteronism screening via the aldosterone-to-renin ratio based upon hypokalemia frequency and severity along with concurrent antihypertensive medication use. We assessed clinical predictors associated with screening via Cox regression. The cohort included 26 533 adults of which only 422 (1.6%) underwent primary aldosteronism screening. When assessed by number of instances of hypokalemia over a 2-year time window, the proportion of eligible patients who were screened increased only modestly from 1.0% (158/15 983) with one instance to 4.8% (71/1494) with ≥5 instances. Among individuals with severe hypokalemia (potassium <3.0 mEq/L), only 3.9% (58/1422) were screened. Among older adults prescribed ≥4 antihypertensive medications, only 1.0% were screened. Subspecialty care with endocrinology (hazard ratio [HR], 1.52 [95% CI, 1.10-2.09]), nephrology (HR, 1.43 [95% CI, 1.07-1.91]), and cardiology (HR, 1.39 [95% CI, 1.14-1.70]) were associated with an increased likelihood of screening, whereas age (HR, 0.95 [95% CI, 0.94-0.96]) and diabetes (HR, 0.66 [95% CI, 0.50-0.89]) were inversely associated with screening. In conclusion, population-level uptake of guideline recommendations for primary aldosteronism screening is exceedingly low. Increased education and awareness are critical to bridge this gap.

Entities:  

Keywords:  aldosterone; cardiovascular disease; hypertension; hypokalemia; potassium

Mesh:

Substances:

Year:  2021        PMID: 34657442      PMCID: PMC8664996          DOI: 10.1161/HYPERTENSIONAHA.121.18118

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  24 in total

1.  Coding accuracy of administrative drug claims in the Ontario Drug Benefit database.

Authors:  Adrian R Levy; Bernie J O'Brien; Connie Sellors; Paul Grootendorst; Donald Willison
Journal:  Can J Clin Pharmacol       Date:  2003

2.  Primary Aldosteronism: unnecessary complexity in definition and diagnosis as a barrier to wider clinical care.

Authors:  Gregory A Kline
Journal:  Clin Endocrinol (Oxf)       Date:  2015-05-07       Impact factor: 3.478

3.  Adherence to consensus guidelines for screening of primary aldosteronism in an urban healthcare system.

Authors:  Maheshwaran Sivarajah; Toni Beninato; Thomas J Fahey
Journal:  Surgery       Date:  2019-09-26       Impact factor: 3.982

4.  Long-term cardio- and cerebrovascular events in patients with primary aldosteronism.

Authors:  Paolo Mulatero; Silvia Monticone; Chiara Bertello; Andrea Viola; Davide Tizzani; Andrea Iannaccone; Valentina Crudo; Jacopo Burrello; Alberto Milan; Franco Rabbia; Franco Veglio
Journal:  J Clin Endocrinol Metab       Date:  2013-09-20       Impact factor: 5.958

5.  Prevalence and incidence of hypertension from 1995 to 2005: a population-based study.

Authors:  Karen Tu; Zhongliang Chen; Lorraine L Lipscombe
Journal:  CMAJ       Date:  2008-05-20       Impact factor: 8.262

6.  Validation of a case definition to define hypertension using administrative data.

Authors:  Hude Quan; Nadia Khan; Brenda R Hemmelgarn; Karen Tu; Guanmin Chen; Norm Campbell; Michael D Hill; William A Ghali; Finlay A McAlister
Journal:  Hypertension       Date:  2009-10-26       Impact factor: 10.190

7.  Primary aldosteronism and hypertensive disease.

Authors:  Lorena Mosso; Cristian Carvajal; Alexis González; Adolfo Barraza; Fernando Avila; Joaquín Montero; Alvaro Huete; Alessandra Gederlini; Carlos E Fardella
Journal:  Hypertension       Date:  2003-06-09       Impact factor: 10.190

8.  Outcomes of a Specialized Clinic on Rates of Investigation and Treatment of Primary Aldosteronism.

Authors:  Yuan-Yuan Liu; James King; Gregory A Kline; Raj S Padwal; Janice L Pasieka; Guanmin Chen; Benny So; Adrian Harvey; Alex Chin; Alexander A Leung
Journal:  JAMA Surg       Date:  2021-06-01       Impact factor: 14.766

9.  Incidence of Atrial Fibrillation and Mineralocorticoid Receptor Activity in Patients With Medically and Surgically Treated Primary Aldosteronism.

Authors:  Gregory L Hundemer; Gary C Curhan; Nicholas Yozamp; Molin Wang; Anand Vaidya
Journal:  JAMA Cardiol       Date:  2018-08-01       Impact factor: 14.676

10.  The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement.

Authors:  Eric I Benchimol; Liam Smeeth; Astrid Guttmann; Katie Harron; David Moher; Irene Petersen; Henrik T Sørensen; Erik von Elm; Sinéad M Langan
Journal:  PLoS Med       Date:  2015-10-06       Impact factor: 11.069

View more
  4 in total

Review 1.  Pathophysiology of bilateral hyperaldosteronism.

Authors:  Kazutaka Nanba; William E Rainey
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2022-06-01       Impact factor: 3.626

Review 2.  Primary aldosteronism - a multidimensional syndrome.

Authors:  Adina F Turcu; Jun Yang; Anand Vaidya
Journal:  Nat Rev Endocrinol       Date:  2022-08-31       Impact factor: 47.564

Review 3.  Updates in hypertension: new trials, targets and ways of measuring blood pressure.

Authors:  Liann Abu Salman; Jordana B Cohen
Journal:  Curr Opin Nephrol Hypertens       Date:  2022-03-04       Impact factor: 3.416

4.  Recalibrating Interpretations of Aldosterone Assays Across the Physiologic Range: Immunoassay and Liquid Chromatography-Tandem Mass Spectrometry Measurements Under Multiple Controlled Conditions.

Authors:  Jenifer M Brown; Richard J Auchus; Brooke Honzel; James M Luther; Nicholas Yozamp; Anand Vaidya
Journal:  J Endocr Soc       Date:  2022-03-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.